Re: Medical Students Can Help Counter Misleading Media and Political Narratives About Strikes
In a rapid response published on April 30, 2026, medical ethicist and barrister Daniel Sokol argues that medical students should refrain from discussing resident doctor strikes with patients. He warns that even brief explanations about workload pressures and patient‑safety motives can appear insensitive or patronising, especially when patients are already anxious about delayed care. The potential loss of trust, complaints, or disciplinary action, he contends, outweighs any benefit of countering misleading media narratives. Sokol’s stance underscores the need for clear boundaries in student‑patient interactions during labor disputes.
EnVVeno Medical Secures FDA IDE Approval for Venous Valve Study
enVVeno Medical has secured FDA investigational device exemption (IDE) approval to launch its pivotal Transcatheter Venous Valve Endoprosthesis (TAVVE) study, targeting severe chronic venous insufficiency (CVI). The trial will begin later this year with a ten‑patient safety cohort, followed by...
5 Ways Chromatography Advances Digital Diagnostics
Chromatography innovations—high‑resolution columns, automated sample‑prep kits, advanced filtration, native software interfaces, and scalable setups—are strengthening the data foundation of digital diagnostics. By delivering cleaner, reproducible chemical data, these technologies enable AI models and electronic health record systems to generate reliable,...
Precision Begins Patient Enrolment for FUNCTION-DMD Trial
Precision BioSciences has activated Arkansas Children’s Hospital as the inaugural site for its Phase I/II FUNCTION‑DMD trial, enrolling boys aged two to seven with Duchenne muscular dystrophy. The study tests PBGENE‑DMD, a first‑in‑class in‑vivo gene‑editing therapy that removes exons 45‑55 to restore...
How Epic Bio Is Leveraging CRISPR without Cutting DNA
Epic Bio, founded by Stanford professor Stanley Qi, is developing an epigenetic editing platform called GEMS that uses the smallest known Cas protein to modulate gene expression without cutting DNA. The system can be delivered in a single viral vector...
3D Systems Clears the EU Bar and Enters Europe’s Denture Market
U.S. printer maker 3D Systems has secured Class IIa MDR certification for its NextDent Jet Base, Jet Teeth materials and NextDent 300 MultiJet printer, unlocking commercial sales of a full‑denture printing system across the European Union starting May 4. The clearance lets dental...
Re: Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)
The phase‑3 PreVenTB trial found that neither VPM1002 nor Immuvac reduced microbiologically confirmed tuberculosis, missing its primary efficacy endpoint. The authors of a BMJ rapid response highlight that the headline claim of 50% efficacy against extrapulmonary TB rests on only...
Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
The European Commission has granted approval for Poherdy, a 420 mg/14 mL interchangeable biosimilar of pertuzumab (Perjeta), covering all approved indications. The decision rests on extensive analytical, pharmacokinetic, efficacy, safety and immunogenicity data that demonstrate equivalence to the reference product. Henlius has...
SportLinc Receives FDA Clearance: Lincotek Targets Orthopedic OEM Market
Lincotek’s SportLinc Syndesmosis Device has secured FDA 510(k) clearance (K252081), enabling commercial launch for ankle syndesmosis injuries. The single‑use system combines a high‑molecular‑weight polyethylene suture with low‑profile titanium buttons and arrives preloaded in a sterile inserter, streamlining operating‑room workflow. Lincotek...
Defect-Engineered Pt/Nb2O5 Boosts Radical-Driven Benzimidazole Production and Hydrogen Evolution Efficiency
Researchers have created a defect‑engineered Pt/Nb₂O₅ catalyst with abundant oxygen vacancies and platinum nanoparticles that dramatically improves photocatalytic benzimidazole synthesis and concurrent hydrogen evolution. The system delivers 4.0 mmol g⁻¹ h⁻¹ production of 2‑methylbenzimidazole and 10.2 mmol g⁻¹ h⁻¹ hydrogen under mild light, surpassing prior benchmarks....
DeNovix Launches Squid™ Full Range Pipette: A Single Device Covering 1 – 1000 µL
DeNovix unveiled the Squid™ Full Range Pipette, a single instrument that handles volumes from 1 µL to 1000 µL, effectively consolidating three to five conventional pipettes. The device uses Dynamic Volume Control™ with a patented tip selector, allowing users to switch between...
Nervous About Rehab? What to Actually Expect During Your First Visit
The article demystifies a first visit to inpatient addiction treatment, outlining the intake assessment, medically supervised detox, and the structured daily schedule that follows. It explains how personalized care plans are created from detailed health and substance‑use histories, and how...
Cold Plunges Under the Microscope: How Advanced Biomarker Testing and Wearable Technology Are Validating the Science of Cold Exposure
Cold plunges are shifting from anecdotal wellness trends to data‑driven interventions, thanks to wearable sensors and advanced biomarker testing. Wearables now capture heart‑rate variability, resting heart rate, and sleep patterns before, during, and after immersion, revealing how the autonomic nervous...
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
A wave of sizable financing rounds swept the biotech sector in late April 2026, with more than $1.3 billion pledged across 15 companies. Beeline Medicines led the pack with a $300 million Series A to advance lupus‑focused small‑molecule and protein therapeutics, while Sidewinder...
Single-Cell Sequencing Reveals Why some CAR-T Therapies Succeed While Others Fail
Researchers reviewed 44 single‑cell RNA sequencing studies covering about 500 patients to pinpoint cellular traits linked to CAR‑T therapy outcomes. The analysis identified exhaustion marker expression, low memory‑like cell fractions, and limited clonal diversity as hallmarks of relapse, while persistent,...
Is Medical Detox the Same as It Used to Be? A Look at Addiction Care in 2026
By 2026 medical detox has shifted from a rigid, uncomfortable process to a data‑driven, patient‑centered experience. Advanced metabolic profiling lets physicians dose buprenorphine, benzodiazepines and other agents with pinpoint precision, while continuous biometric monitoring catches vital‑sign changes instantly. Intravenous nutrient...
Map: Most States Are at Risk for Measles Outbreaks
Measles cases in the United States have surged from just 13 in 2020 to 2,228 in 2025, with nearly 1,800 reported in the first half of 2026. The spike follows a sharp decline in kindergarten‑age vaccination rates, which fell below...
What Drove Down America’s Fentanyl Deaths?
U.S. fentanyl overdose deaths fell sharply after mid‑2023, dropping nearly 50% by September 2025. Researchers link the decline to a supply shock, citing reduced fentanyl seizures, lower purity, and a surge in Reddit mentions of a "fentanyl drought." The shock appears...
Why Some Hospitals Won’t Be Able to Comply With Upcoming HIPAA Updates
The Department of Health and Human Services will finalize the first major HIPAA overhaul in more than a decade, scrapping the distinction between “required” and “addressable” rules and making every security provision mandatory. New mandates cover two‑factor authentication, data encryption,...
Can Your Surroundings Make or Break Your Recovery? Why Environment Matters in Addiction Treatment
Addiction recovery hinges on more than medication and willpower; the surrounding environment plays a decisive role. Removing patients from familiar triggers, immersing them in nature‑rich settings, and providing a warm, structured atmosphere lower stress hormones and enable deeper therapeutic work....
Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier
Researchers have shown that disrupting the internal limiting membrane (ILM) enables transplanted human pluripotent stem cell‑derived retinal ganglion cells (hRGCs) to survive, migrate, and mature in the retina of mice, rats and non‑human primates. In eyes with a genetically incomplete...
New Copper Nanozyme Shows Powerful Tumor Suppression with High Precision
Researchers at the Chinese Academy of Sciences have created a coordinatively unsaturated copper single‑atom nanozyme (Cu‑N₂‑CDs) that exhibits markedly higher catalytic activity than traditional Cu‑N₄ nanozymes. The unsaturated Cu‑N₂ sites boost H₂O₂ adsorption by 3.49 times and generate hydroxyl radicals 3.62 times...
The Knowledge, Attitude, and Practice Score on Oral Nutrition Supplementation Is Inversely Associated with Malnutrition Risk of Tumor Patients During...
A multicenter cross‑sectional study of 1,737 Chinese cancer patients undergoing radiotherapy found that 70.1% were at risk of malnutrition. Researchers measured patients' knowledge, attitude, and practice (KAP) toward oral nutrition supplements (ONS) and discovered that higher KAP scores were independently...
Association Between Planetary Health Diet Index and Lung Cancer Risk in 106,542 Participants: A Prospective Cohort Study
A prospective analysis of 106,542 participants from the PLCO trial found that higher adherence to the Planetary Health Diet Index (PHDI) was associated with a 29% lower risk of lung cancer over an average 8.8‑year follow‑up. Individuals in the highest...
Nutritional Properties of Extracellular Vesicle-Like Particles From Sophora Flavescens and Periplaneta Americana with Effects on Streptozotocin-Induced Diabetic Wound Healing in...
Researchers combined extracellular vesicle‑like particles (EVLPs) from the medicinal plant Sophora flavescens and the insect Periplaneta americana, creating a cross‑kingdom nano‑nutritional formulation (SF‑PA‑EVLPs). In streptozotocin‑induced diabetic rats, high‑dose SF‑PA‑EVLPs achieved roughly 90% wound closure within 14 days, outperforming the standard...
Dr. Reddy’s Announces Health Canada Approval of Generic Semaglutide Injection
Dr. Reddy’s Laboratories received a Notice of Compliance from Health Canada, becoming the first firm to secure market authorization for a generic semaglutide injection in Canada. The approval covers both 2 mg and 4 mg pen formulations, and the company is preparing...
Subtle Changes in Everyday Tasks Can Signal Alzheimer’s Risk Years Before Memory Loss
New research shows that persistent difficulties in everyday activities—such as cooking, shopping, or driving—can signal Alzheimer’s disease risk years before memory loss becomes apparent. Longitudinal studies found these functional impairments are linked to higher incidence of Alzheimer’s and to disease‑specific...
New Genome Editing Method Could Swap Entire Genes and Correct 1000 Mutations at Once
Scientists have unveiled a new genome‑editing platform called prime assembly that can insert DNA segments up to 11,000 base pairs, enabling the replacement of entire genes rather than single‑point edits. The method uses overlapping flaps to attach donor DNA without...
Cartesian Therapeutics Inc (RNAC) Q1 2026 Earnings Call Transcript
Wave Life Sciences reported a Q1 net loss of $46.9 million, with cash reserves of $243.1 million expected to fund operations into 2027. The DMD candidate WVE‑N531 delivered a statistically significant 3.8‑second improvement in time‑to‑rise and 7.8% average dystrophin expression,...
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals reported $172 million total revenue for 2025, driven by $124.8 million from its menin inhibitor RevuForge and $151.6 million from the chronic‑GVHD therapy Nictimvo. RevuForge posted 38% quarter‑over‑quarter revenue growth and reached roughly 50% penetration of the KMT2A AML population, while...
Causal Evidence of Task-Switching Costs in Organ Transplantation
A new empirical study provides causal evidence that task‑switching interruptions add measurable time and risk to organ transplantation procedures. By linking real‑world operating‑room data with cognitive‑psychology models, the researchers show each intra‑operative switch adds roughly 12 minutes of cold‑ischemia time,...
Novocure Ltd (NVCR) Q1 2026 Earnings Call Transcript
NovoCure reported a record $655 million in net revenue for 2025, an 8% year‑over‑year increase driven by strong international patient growth. The company secured FDA approval for Optune Pax, its TTFields device targeting locally advanced pancreatic cancer, and began launch preparations in...
Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Transcript
Alnylam reported a strong Q1 2021 performance, with total product sales reaching $135.8 million, an 89% year‑over‑year increase. ONPATTRO generated $102 million in revenue, growing 13% quarter‑over‑quarter, while newly launched OXLUMO contributed $9 million and GIVLAARI $24.7 million. The company announced positive Phase 3 data...
Commentary: Clinical Knowledge Gaps Hinder Fight Against Smoking in Central Asia and Caucasus
Public health officials in Central Asia and the Caucasus are battling entrenched smoking rates, but a new Healthy Initiatives survey reveals that doctors lack essential cessation training. In Kazakhstan, more than four‑fifths of physicians have never received formal counseling education,...
Baxter International Inc (BAX) Q1 2026 Earnings Call Transcript
Baxter International reported $3.0 billion in global sales for the quarter, an 8% reported increase and 3% operational growth, while adjusted earnings per share fell to $0.44, missing internal expectations. Margin pressure stemmed from an unfavorable product mix, higher supply costs...
Pro-Dex Inc (PDEX) Q3 2026 Earnings Call Transcript
Becton Dickinson reported Q3 fiscal 2025 revenue of $5.5 billion, up 8.5% year‑over‑year and 3% organically, while adjusted gross margin rose to 54.8% and adjusted EPS reached $3.68, beating expectations. The company announced a definitive agreement to divest its Biosciences and...
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx reported total Q3 2025 revenue of $110.3 million, a 12% increase year‑over‑year, driven primarily by a 92% surge in IBSRELA sales to $78.2 million. XPHOZAH contributed $27.4 million, marking a 9% sequential rise, and the company raised its full‑year IBSRELA revenue guidance...
Amgen Inc (AMGN) Q1 2026 Earnings Call Transcript
Amgen reported first‑quarter 2026 sales of $5.6 billion, a 4% year‑over‑year increase, driven by six high‑growth products that contributed 70% of total revenue. Repatha, Evenity, Test Buyer, TEPEZZA and the rare‑disease portfolio posted double‑digit growth, while legacy brands Prolia and XGEVA...
Select Medical Holdings Corp (SEM) Q1 2026 Earnings Call Transcript
Select Medical reported Q4 2025 revenue growth of over 6% while adjusted EBITDA fell 10% to $104.7 million, driven by an unexpected $15 million health‑insurance expense and $6 million variable discounts in outpatient rehab. The Board is evaluating a nonbinding take‑private proposal...
Cigna Group (CI) Q1 2026 Earnings Call Transcript
Cigna reported full‑year adjusted revenue of $275 billion, an 11% increase, and adjusted earnings per share of $29.84, up 9% year over year. Specialty and care services drove a 14% revenue jump to $26.7 billion, while specialty script volume grew 13%. The...
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics reported Q1 2026 revenue of $2.8 million, entirely from its Gilead collaboration, and ended the quarter with $978.7 million in cash, extending its runway into the second half of 2028. The company completed enrollment and dosing for the Phase Ib atopic...
Angiocrine Signaling Drives Liver Fibrosis: From Mechanism to Early Clinical Translation
Researchers led by Hu et al. discovered that ROCK2 activity in liver sinusoidal endothelial cells is a pivotal driver of liver fibrosis. Single‑cell transcriptomics and knockout models revealed that ROCK2‑mediated cytoskeletal remodeling releases angiocrine factors that activate hepatic stellate cells. Early...
Organon & Co (OGN) Q1 2026 Earnings Call Transcript
Organon reported flat 2025 revenue of $6.2 billion and adjusted EBITDA of $1.9 billion, both reflecting a 3% decline year‑over‑year. The company highlighted a $390 million net cash inflow from the Jada system divestiture, earmarked for debt reduction to bring net leverage below...
Medical Properties Trust Inc (MPT) Q1 2026 Earnings Call Transcript
Medical Properties Trust reported Q1 2024 results, highlighting $1.6 billion of liquidity transactions and a $900 million cash sale of 75% of its Utah hospital portfolio while retaining a 25% interest. The company reduced net debt by $1.6 billion, now holding about $900 million...
Labcorp Holdings Inc (LH) Q1 2026 Earnings Call Transcript
Labcorp reported full‑year 2025 enterprise revenue up more than 7% and adjusted EPS rising 13%, driven by strong Diagnostics and Central Laboratory performance. Fourth‑quarter revenue reached $3.5 billion, margins expanded 120 basis points, and free cash flow hit $1.2 billion despite a seasonal...
Merit Medical Systems Inc (MMSI) Q1 2026 Earnings Call Transcript
Merit Medical Systems reported Q1 2021 GAAP revenue of $249 million, a 2.2% year‑over‑year increase, driven mainly by a 4.9% rise in international sales and modest U.S. growth. On a constant‑currency basis the company posted 0.6% revenue growth, surpassing its prior...
Long-Lived Immune Cells Show Promise Against Cancer in World-First Trial
A world‑first clinical trial tested CAR‑T therapy enriched with stem‑cell memory T cells, a long‑lived immune subset. In a small cohort of 11 patients with refractory blood cancers, five achieved complete remission and one partial remission, outperforming historical outcomes of...
AC Immune SA (ACIU) Q1 2026 Earnings Call Transcript
Eli Lilly reported a 56% year‑over‑year revenue surge in Q1 2026, propelled by its incretin portfolio—Mounjaro and Zepbound generated $12.8 billion in global sales. The company secured FDA approval for Koundeo, the first oral GLP‑1 for obesity, and logged over 20,000...
Encompass Health Corp (EHC) Q1 2026 Earnings Call Transcript
Encompass Health reported a strong Q1 2019, with consolidated revenue up 7.5% to $1.124 billion and adjusted EBITDA rising 8.8% to $242.9 million, delivering $1.04 earnings per share. The company announced a definitive agreement to acquire Alacare Home Health and Hospice, adding 46...
Option Care Health Inc (OPCH) Q1 2026 Earnings Call Transcript
Option Care Health reported fiscal 2025 net revenue of $5.6 billion, a 13% increase driven by balanced growth in acute and chronic infusion therapies. Adjusted EBITDA rose 6% to $471 million, delivering an 8.3% margin, while adjusted diluted EPS climbed 9% to...